[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session .

Author Index: A

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
309 - Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML)
422 - Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience
890 - Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts)
1706 - Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine
1719 - A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure
1720 - Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies
2035 - Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents
2807 - Impact of Cytogenetics and Cytogenetic Response On Outcome in MDS Treated with Azacitidine (AZA)
2808 - Effector CD4+CD45RA-CD25brightFoxp3bright Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status
2809 - Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q
2814 - Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM)
3103 - Equivalent Outcome Between Reduced Intensity Versus Conventional Myeloablative Conditioning Hematopoietic Stem Cell Transplantation for Patients Older Than 35 Years with Acute Myeloid Leukemia
3811 - Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML)
3812 - Prognostic Factors of Severe Infections, and Effect of Primary Anti-Infectious Prophylaxis in MDS Patients Treated with Azacitidine (AZA). A Single Center Study On 144 Patients
3833 - Azacitidine Treatment for Lenalidomide (LEN)-Resistant Myelodysplastic Syndrome (MDS) with Del 5q
3835 - NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS)
1261 - Anemia Associated with Increased IL-6 and IL-8 Levels Predicts for Worse Progression-Free Survival in T-Cell and NK-Cell Large Granular Lymphocyte (LGL) Leukemia but Is Improved by Treatment with Cyclophosphamide
1472 - Impact of Day 28 Absolute Lymphocyte Count On Outcome of Hematopoietic Cell Transplant (HCT) in CR1 for Adult Patients with Acute Lymphoblastic Leukemia
1487 - Vancomycin-Resistant Enterococcus (VRE) Bacteremia During Acute Myeloid Leukemia (AML) Induction Therapy Is an Independent Predictor of Poor Outcome
1696 - Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics
1698 - Whole Exome Sequencing to Predict Response to Hypomethylating Agents in MDS
2589 - Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-Related AML
2603 - Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia
2612 - Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia
3535 - Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL)
3595 - A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/ Refractory Acute Myeloid Leukemia
3597 - A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML)
3791 - Pathway Analysis of Molecular Mutations Can Modify Morphologic, Cytogenetic and Prognostic Risk Stratification Schemes in Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN), and Secondary Acute Myeloid Leukemia (AML)
3804 - Molecular Mutations in U2AF1 Are Most Commonly Found in Del20q Myelodysplastic Syndromes but Do Not Lead to Poor Prognosis in This Karyotypic Subtype
3805 - The Molecular and Cytokine Profile of Triple-Negative (JAK2 V617F, JAK2 exon 12, MPL negative) Myelofibrosis, a Myeloproliferative Neoplasm with Distinct Clinico-Pathologic Characteristics
3831 - Patients with SF3B1 Mutation Have Good Prognosis Even in the Presence of Other Poor Prognostic MDS Features and Have Better Outcomes During Treatment with Low Intensity Chemotherapy
56 - A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
59 - A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
60 - Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T‑Cell and NΚ‑Cell Lymphomas
153 - Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma
156 - The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma
582 - Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma
686 - The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study
687 - Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)
797 - Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression
904 - Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up
1618 - Primary Breast Diffuse Large B Cell Lymphoma:  A Distinct Clinical Entity
2687 - A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma:  an Eastern Cooperative Oncology Group Study (E3402)
2745 - Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
2746 - A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas:  Interim Results
3703 -  in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma:  Analysis of Immune Responses
1390 - Clinical, Cellular and Molecular Differences Between Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia: Insights Into Mechanisms of Resistance
1438 - ABC Transporter Expression in Acute Myeloid Leukemia: Association with in Vitro Cytotoxicity and Prognostic Markers
1446 - Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors
2130 - High Expression of p53 and Growth Differentiation Factor-15 in Beta-Thalassemia
2785 - RNA Expression and Polymorphisms in Imatinib Influx and Efflux Transporters Influence Molecular Response to Imatinib Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia
3202 - Molecular and Functional Characterization of Two Novel Missense Mutations in Iron Transport Protein Causing Hypochromic Microcytic Anemia and Hemosiderosis
3380 - Community Based Evaluation of Prevalence of Inhibitors in Patients with Severe Hemophilia A in India and Their Correlation with Environmental and Genetic Factors
3552 - Patterns of Immune Reconstitution in Patients with Acute Promyelocytic Leukemia Treated with Single Agent Arsenic Trioxide and Its Impact On Time to Molecular Remission
3607 - Mechanism of Synergy Between Bortezomib and Arsenic Trioxide in Acute Promyelocytic Leukemia and Clinical Efficacy in Relapsed Patients
4160 - Clinical Profile and Outcomes of Patients with β Thalassemia Major and Hepatitis C Virus Infection Undergoing an Allogeneic Stem Cell Transplant
4199 - A Phase II Study Using Post-Transplant Cyclophosphamide (PTC) As Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergoing HLA Matched Sibling Donor Stem Cell Transplant (SCT) for Severe Aplastic Anemia (SAA)
923 - Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)
1371 - Targeting Metabolic Pathways for Leukemia Treatment
1678 - The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis
1680 - The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib
2784 - Delayed Cytogenetic Response and Reduced Rate of Major Molecular Response Associated to Increased Body Mass Index At Baseline in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib
2797 - Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib
3733 - Proteomic Signature of CD34+ Cells From Chronic Myeloid Leukemia Patients
3742 - Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to Imatinib
3769 - Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib
3784 - Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307
3850 - Lenalidomide in Myelodysplastic Syndromes with 5q Deletion. Results From the Italian National Cancer Registry
4234 - Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy
123 - Identification of Novel Somatic Mutations, Regions of Recurrent Loss of Heterozygosity (LOH) and Significant Clonal Evolution From Diagnosis to Relapse in Childhood AML Determined by Exome Capture Sequencing – an NCI/COG Target AML Study
125 - Clinically Significant Mutations, Deletions and Translocations Involving ETV6 Identified by Whole Genome and Whole Exome Sequencing; Report From NCI/COG Target AML Initiative
127 - Hematopoietic Cell Transplant Versus Chemotherapy As Consolidation Treatment for Pediatric AML with Poor-Risk Cytogenetics
529 - Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure.  Report From Children’s Oncology Group
537 - NUP98/JARID1A Is a New Recurrent Genetic Abnormality in Pediatric Acute Megakaryoblastic Leukemia with a Distinct HOX-Gene Expression Pattern
884 - Clinical Impact of Additional Cytogenetic Aberrations and Treatment in Pediatric t(8;21)-Positive AML: Results from an International Retrospective I-BFM-SG Study
1278 - RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia
1287 - Genome Wide Promoter Methylation Patterns Predict AML Subtype Outcomes and Identify Novel Pathways Characterizing Diagnostic and Relapsed Disease in Children
1385 - WT1 snp rs16754 Genotype Predicts Treatment Related Mortality (TRM) in African-American and Asian Pediatric AML Patients: A Report From the Children’s Oncology Group
1403 - Constitutional Telomerase-Associated Gene Variants Associated with Chemotherapy-Related Toxicities in Pediatric Acute Myeloid Leukemia (AML)
1414 - Outcome of Pediatric Patients with Acute Myeloid Leukemia and -5/5q -Abnormalities Enrolled On Five Children’s Oncology Group Acute Myeloid Leukemia Treatment Protocols
1425 - Expression of RUNX1 and RUNX1T1 Correlates with Cytogenetic Subgroups in Pediatric AML: A Report From the Children's Oncology Group
1478 - Effectiveness of Supportive Care Measurements to Reduce Infections During Induction for Children with Acute Myeloid Leukemia: A Report From the Children’s Oncology Group
2388 - Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children’s Oncology Group
2516 - Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Münster AML Study Group
2530 - High EVI1 expression Is Associated with MLL rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children’s Oncology Group
2541 - Acute Myeloid Leukemia with t(6;9)(p23;q34) Is Associated Poor Outcome in Childhood AML Regardless of FLT3/ITD Status, A Report From Children’s Oncology Group
2546 - Novel IL23R Splice Variant Is Associated with Worse Prognosis in Pediatric Patients with AML
2550 - Novel IRF8 Splice Variants Are Validated As a New Prognostic Biomarker for Adverse Outcome in an Independent Population of Pediatric Patients with AML
2553 - Elevated BAALC Gene Expression Lacks Clinical Significance in Pediatric AML- A Report From the Children’s Oncology Group
3519 - Integrative Network Analysis of Pediatric AML Whole Genomes, cDNA Expression and Clinical Data Elements Reveals Shared As Well As t(8;21), Inv16 and MLL Specific Pathways; A Report From COG/NCI Target AML Initiative
3580 - A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia: A Children’s Oncology Group (COG) Study
3604 - AAML0523: A Report From the Children’s Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia
403 - Mixed Phenotype Acute Leukemia, T/Myeloid, NOS (MPAL-TM) Has a High DNMT3A Mutation Frequency and Carries Further Genetic Features of Both AML and T-ALL: Results of a Comprehensive Next-Generation Sequencing Study Analyzing 32 Genes
408 - Comparison of Mutation Patterns Between Diagnosis and Relapse in 444 Patients with Acute Myeloid Leukemia Shows High Variability of Stability and Influence On Time to Relapse
657 - The Landscape of RUNX1 Mutations in Acute Myeloid Leukemia: Investigations On Stability of Mutations At Relapse and Utility As a Marker for Minimal Residual Disease
709 - SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients
782 - Recurrent Mutations of Multiple Components of Cohesin Complex in Myeloid Neoplasms
783 - Comprehensive Profiling of Somatic Mutations Which Define Primary Disease and Relapse in Various Acute Leukemia Subtypes
1376 - High BAALC Expression in Cytogenetically Normal Acute Myeloid Leukemia Strongly Correlates with Adverse Markers Such As RUNX1mut, MLL-PTD and FLT3-ITD and Is Useful for Disease Monitoring
1595 - Cyclin D1 (CCND1) mRNA Expression Assessed by Real-Time PCR Is Increased in Patients with Mantle Cell Lymphoma and Contributes to Diagnosis in B-Cell Lymphoma Cases
1768 - Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1
2503 - Sole Trisomy 8 in AML: Concomitant Molecular Markers, Stability of Genetic Patterns and Impact On Outcome
2661 - Flow Cytometric Assessment of the T-Cell Receptor Vβ Repertoire Identifies Clonal T-Cell Populations with High Specificity and Sensitivity
2679 - Evaluation of BRAFV600E, NRAS and KRAS Mutations As Well As IGHV Usage for Diagnostic Use in Hairy Cell Leukemia, Hairy Cell Leukemia-Variant and Splenic Marginal Zone Lymphoma
2806 - Prognostic Impact of Multiparameter Flow Cytometry in Patients Analyzed for Suspected MDS
3798 - Analysis of SF3B1 in a Large Cohort of Refractory Anemia with Ring Sideroblasts with/without Marked Thrombocytosis (RARS-T/RARS) in an European Multicentre Study Reveals a High Incidence (86.3%) of Mutations and an Independent Favorable Association with Outcome
326 - CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis
330 - Intracellular NAD+ Depletion Enhances Bortezomib-Induced Myeloma Cytotoxicity
447 - Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma
450 - Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis
565 - Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment
578 - Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation
723 - Compromised Nuclear Sirtuins Activity Sensitizes BRCA-Proficient multiple Myeloma Cells to DNA Damage Agents
725 - The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma
727 - MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
897 - MYD88 L265P Promotes Survival of Waldenstrom’s Macroglobulinemia Cells by Activation of Bruton’s Tyrosine Kinase
942 - TAS-117, a Novel Selective Akt Inhibitor Demonstrates Significant Growth Inhibition in Multiple Myeloma Cells in Vitro and in Vivo
1812 - Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma
1835 - CRM1 Inhibition Abrogates Osteoclast Formation and Bone Resorption Via Inhibition of RANKL-Induced NFκB While Sparing Osteoblastogenesis: Further Therapeutic Implication in Multiple Myeloma
1847 - Targeting Aminopeptidases by Tosedostat (TST) (CHR2797), Alone and with LBH589, Induces Significant Cytotoxicity Against Human Multiple Myeloma (MM) Cells
2386 - Integrating Gene and Mir Expression Profiles and Regulatory Network Structures to Define Aberrent Feed Forward Loops with Functional and Clinical Implications in Myeloma
2941 - MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile
3165 - Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma – Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials
3959 - Targeting Mcl-1 for Multiple Myeloma (MM) Therapy: Drug- Induced Generation of Mcl-1 Fragment Mcl-1128-350 Triggers MM Cell Death Via c- Jun Upregulation
3980 - The Multiple Myeloma Research Foundation (MMRF) CoMMpassSM Study: A Longitudinal Study in Newly-Diagnosed Multiple Myeloma Patients to Assess Genomic Profiles, Immunophenotypes and Clinical Outcomes
3986 - Reprogramming Aberrant B Cell-Subsets to Improve Immune Function in Multiple Myeloma
3995 - Cells of the Osteoblast Lineage Confer Myeloma Cell Resistance to Established and Investigational Therapeutic Agents
4042 - BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity
4052 - Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study
4053 - Treatment Outcomes with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDex) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) and Del(17p13) and/or t(4;14)(p16;q32) Cytogenetic Abnormalities Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT)
4070 - Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure
4072 - Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes
4077 - Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study
4078 - A Clinically Relevant Zebrafish in Vivo Model of Human Multiple Myeloma (MM) to Study Disease Biology and Preclinical Therapeutic Efficacy
43 - Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)
142 - Mobilization and Elimination  of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib :  Results From a Phase I  Trial in Relapsed/Refractory  AML Patients
360 - Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse
534 - Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by the cIAP1-NIK Axis and Confers Resistance to SMAC Mimetic Birinapant-Induced Cell Death in AML
613 - A Novel Role for Mesenchymal Stem/Progenitor Cells As Hypoxia Sensors During Initiation of Neo-Vasculogenesis in Vivo
675 - Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia
678 - BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS
783 - Comprehensive Profiling of Somatic Mutations Which Define Primary Disease and Relapse in Various Acute Leukemia Subtypes
870 - Prognostic Impact and Targeting of CRM1 in Acute Myeloid Leukemia
893 - ARC Is Regulated by MAPK and PI3K and Confers Drug Resistance and Survival Advantage to AML in Vitro and in Vivo
1286 - The Hsa-Let-7a miRNA Enhances Ara-C Induced Apoptosis in Human Acute Myeloid Leukemia Cells
1417 - Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy
1516 - Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia
1519 - Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation
1523 - Leukemia Microenvironment and Pathologic Hypoxia: Sensitivity to Hypoxia-Activated Cytotoxin TH-302
2354 - Suppression of Mir-93 May Regulate Anti-Oxidant Metabolism in Mesenchymal Stromal Cells Derived From Acute Myeloid Leukemia Patients
2355 - Proteomic Profiling of AML Bone Marrow-Derived Mesenchymal Stem Cells (MSC) Reveals Marked Differences From Normal MSC
2438 - Molecular Mechanisms of Antitumor Activity of the Selective Inhibitor of Nuclear Export (SINE) CRM1 Antagonist KPT-185 in Mantle Cell Lymphoma
2582 - Molecular Mechanisms of Pro-Survival and Differentiating Function of Bone Marrow-Derived Adipocytes On Acute Monoblastic Leukemia Cells
2626 - Apoptosis Repressor with Caspase Recruitment Domain (ARC) Increases AML Cell Migration and Adhesion in Vitro and in Vivo by Regulating Leukemia-Stroma Interactions
2773 - Analysis of Dasatinib-Induced Molecular Mechanisms of Apoptosis in Hypoxia-Adopted CML Cells Utilizing Quantitative Proteomics Technology
2987 - Organotypic Epigenetic Signature Predicts Bone and Marrow Niche Forming Capacity of Stromal Progenitors in a  Novel Mouse Model in Vivo
3468 - Unique Effects of p53-/- Leukemic Cells On Mesenchymal Stromal Cell Gene Expression Profile in Vitro
3469 - Exosomes Mediate Communication Between the Microenvironment and Leukemic Cells in Acute Myeloid Leukemia
3518 - NF-κB Activation in Mesenchymal Stromal Cells Mediates Leukemia Cell Chemoresistance
3543 - TGF-β1 Supports Leukemia Cell Survival Via Negative Regulation of FLI-1 Transcription Factor, ERK Inactivation and MMP-1 Secretion
3557 - Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies
3572 - Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen
3591 - Combination of Crenolanib with Sorafenib Produces Synergistic Pro-Apoptotic Effects in FLT3-ITD-Inhibitor-Resistant Acute Myelogenous Leukemias with FLT3 Mutations
3615 - Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia
3625 - SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML
775 - Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells
1800 - A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
1942 - Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT)
1949 - Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease
2004 - Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance
2691 - Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL)
2955 - Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma
3866 - Lymphocyte Cytosolic Protein 1 (LCP1) Is a Membrane Associated Molecular Target in Chronic Lymphocytic Leukemia and Is Activated in Microenvironment Signaling
4192 - Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)
4286 - The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma
149 - Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era
600 - Patients with Immunoglobulin Light Chain Amyloidosis (AL) Undergoing High Dose Chemotherapy with Autologous Stem Cell Transplantation (ASCT)  have Superior Outcomes As Compared to Patients with Multiple Myeloma (MM)
684 - Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
689 - Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study
798 - Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma
1525 - Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution
1527 - Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL)
1546 - Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era:  A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource
1554 - IL-21 and IL-6 Mediate Interactions Between T Cells and Malignant B Cells in the Bone Marrow Microenvironment in Waldenstrom’s Macroglobulinemia
1563 - Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI
1604 - EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (-) Counterparts: Results From University of Iowa/Mayo Clinic SPORE
2634 - Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL)
2688 - Biologic Activity of STAT5A and STAT5B in Waldenstrom’s Macroglobulinemia
2699 - MYD88 Pathway Activation in Lymphoplasmacytic Lymphoma Drives Tumor Cell Growth and Cytokine Expression
2700 - The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma
2702 - CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis
2741 - LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL
3637 - Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies
3689 - Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma
3701 - Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant
3723 - Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia
226 - Prostaglandin E2 (PGE2) Alters the Molecular and Functional Properties of Umbilical Cord Blood T Cells Via Modulating Wnt/β-Catenin Signaling
457 - Multicenter Study of “off-the-Shelf” Third Party Virus-Specific T Cells (VSTs) to Treat Adenovirus (Adv), Cytomegalovirus (CMV) or Epstein Barr Virus (EBV) Infection After Hemopoietic Stem Cell Transplantation (HSCT)
466 - Plasma ST2 Concentrations Predict Development of Acute Gvhd and Non-Relapse Mortality
735 - SNP-Based Bayesian Networks Define Oral Mucositis Risk in Patients Receiving Stomatotoxic Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation
738 - Results of a Large Prospective Study On the Use of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Hematopoietic Stem Cell Transplant (HSCT). Early Intervention Improves Outcome – Updated Results of a Treatment IND (T-IND) Expanded Access Protocol
739 - Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402
744 - A Phase I Study of Alemtuzumab Dosing for Steroid-Refractory Chronic Graft-Versus-Host Disease
1892 - Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL)
1927 - BK Virus Disease Following Allogeneic Stem Cell Transplantation: A Cohort Analysis  
2010 - Allele Matching At HLA-C or DRB1 Is Associated with Improved Survival After Reduced Intensity Double Umbilical Cord Blood Transplantation
3058 - Airway Dilation in Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation
3069 - Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation
3128 - Low Dose Busulfan Is Associated with Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation
4136 - Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation
4174 - BK Virus Reactivation After Double Umbilical Cord Blood Transplantation in Adults Correlates with Tregs and Delayed Reconstitution of CD4+ and CD8+ T Effector Cells
4175 - Recovery of Thymic Epithelial Cells and T Cell Immune Reconstitution After Cord Blood Transplantation in Adults Depends On Angiogenesis and Neovascularization
LBA-4 - Next-Generation Sequencing for the Identification of Transplantation-Associated Pathogens
129 - Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA)
540 - Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of “Acute Myeloid Leukemia, Not Otherwise Specified” in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center
592 - Impact of Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry Pre and Post Transplantation, On Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
655 - Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission
811 - A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma
963 - Prospective Phase II Multicenter Study of Conditioning with Treosulfan, Fludarabine and Low-Dose (2 Gy) Total Body Irradiation Followed by Hematopoietic Cell Transplantation From Related or Unrelated Donors for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
1278 - RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia
1418 - The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia
1479 - NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML)
1924 - A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
1995 - Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignancies Is Comparable to Unrelated Donor Transplantation: A Retrospective Single-Center Study
2489 - Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials
2499 - Morphology Vs. Multiparameter Flow Cytometry in Evaluation of AML in Cerebrospinal Fluid (CSF)
2590 - A Scoring System for Prediction of FLT3-ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia
2598 - Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery
2603 - Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia
2622 - Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study
3535 - Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL)
3584 - A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients
3594 - Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
4164 - Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT
68 - Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?
163 - A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
875 - PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients
915 - Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial
1215 - Contrasting Effects of Enhanced Sirt1 Activity in Normal and BCR-ABL1-Depedent Haematopoiesis
2555 - A Novel Splice Site Variant of hOCT-1 and Response to Imatinib
2591 - Defective Natural Killer (NK) Receptor Expression and Effector Function in Acute Myeloid Leukemia Partially Normalize At Remission and Predict Response to Chemotherapy
2789 - Can Targeted Therapy for CML Still Learn From Transplant? Using Post-transplant RQ-PCR monitoring to Clarify the Importance of the Depth of Molecular Remission On the Risk of Subsequent Relapse
2798 - Assessment of Early Cytogenetic Response As a Predictor of Long-Term Clinical Outcomes in a Phase 1/2 Study of Bosutinib in Chronic Phase CML
3747 - Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial
3749 - Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial
3760 - Is Major Molecular Response a Safe Haven Against Blast Crisis in Cml Patients Treated with Imatinib?
3763 - Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial
1422 - Risk-Adapted, MRD-Refined Therapeutic Approach for the Treatment of Acute Myeloid Leukemia: From a Single Center Experience to the Cooperative Gimema Protocol AML1310
1975 - Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT
1987 - Unmanipulated Graft Transplantation From Family Haploidentical Donors: A Survey On 183 Adult Patients with Acute Leukemias On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
2005 - Validation of the Cibmtr Score in Predicting the Outcome of Hematopoietic Stem-Cell Transplantation in AML Patients Not in Complete Remission At the Time of Conditioning: A Retrospective Analysis On Behalf of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)
2033 - Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party
3083 - Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission?
3093 - Haploidentical Mismatched Allogeneic Versus Autologous Hematopoietic STEM CELL Transplantation in Adult Patients with ACUTE Myeloid Leukemia (AML) in First Complete Remission (CR1): A  Pair-Matched Analysis From the Acute Leukemia Working Party of EBMT
3117 - Impact of Myeloablative and Reduced Intensity Conditioning On Outcomes After Unrelated Cord Blood Transplantation for Adults with Acute Lymphoblastic Leukemia
3122 - Unmanipulated, G-CSF-Primed Bone Marrow Transplantation From Haploidentical Donor for Patients with High-Risk Acute Myeloid Leukemia
4094 - Long Telomere Length of White Blood Cells Following Umbilical Cord Blood Transplant (UCBT): Is Hematopoiesis Younger in UCBT Recipients Compared to Healthy Age-Matched Controls ?
4153 - Comparative Efficacy Analysis of Busulfan Dose Intensity Between Two Reduced Intensity Conditioning Regimens (FB2 vs. FB4) for Allogeneic HCT for AML in First Complete Remission: A Report From the EBMT Acute Leukemia Working Party
1918 - Outcome and Prognostic Index for Reduced-Intensity Allogeneic Stem Cell Transplantation (RIST) for Elderly Patients with De Novo Acute Myeloid Leukemia (AML): A Study From the AML Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)
1922 - Intravenous Busulfan-Based Myeloablative Conditioning Is Comparable to TBI-Based Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Recipients with Acute Myeloid Leukemia: A Nationwide Retrospective Study From the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
2641 - Prospective Nationwide Observational Study of Hepatitis B Virus (HBV) DNA Monitoring and Preemptive Antiviral Therapy for HBV Reactivation in Patients with B-Cell Non-Hodgkin Lymphoma Following Rituximab Containing Chemotherapy: Results of Interim Analysis
3046 - Clinical Factors Predicting the Response of Acute Graft-Versus-Host Disease to Corticosteroid Therapy
3095 - Older Age Increases Non-Relapse Mortality in Patients with Grade II–IV Acute Gvhd After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Analysis of the Japanese Trump Database
3113 - Impact of Parental Donor Type On Outcomes After HLA-Matched and HLA-Mismatched T-Cell-Replete Hematopoietic Cell Transplantation for Patients with Leukemia: A Retrospective Cohort Study
3118 - Unfavorable Outcome of Single-Unit Umbilical Cord Blood Transplantation for Elderly Patients with Myelodysplastic Syndromes
4185 - The Impact of ATG/Alg in Preconditioning On the Allogeneic Stem Cell Transplantation for Patients with Acute Leukemia
196 - Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis : An Illustration of Clonal Dynamic During Disease Course. an IFM Study
598 - The Combination of ISS 3, High LDH and t(4;14) and/or Del(17p) Identify a Simple Prognostic Index for Overall Survival in Patients Treated with Novel Agents-Based Induction Therapy and Front-Line Autologous Stem Cell Transplantation, and Allow the Definition of a Subgroup of Patients At High-Risk of Early Death From Progressive Disease
749 - Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies
933 - 1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients
1975 - Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT
2961 - Prolonged Overall Survival with Pomalidomide and Dexamethasone in Myeloma Characterized with End Stage Disease
3096 - Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM)
3116 - Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs
3993 - Are Stromal Cells of Adipose Tissue From Multiple Myeloma Patients Are Normal ?  A Comparison of Adipose Derived Stromals Cells From Healthy Donors and Multiple Myeloma Patients
4075 - Efficacy of Lenalidomide in Patients with Multiple Myeloma Previously Treated by Melphalan-Prednisone and Thalidomide
569 - Characterization of TFDP1 As Novel Regulatory Gene in Multiple Myeloma
598 - The Combination of ISS 3, High LDH and t(4;14) and/or Del(17p) Identify a Simple Prognostic Index for Overall Survival in Patients Treated with Novel Agents-Based Induction Therapy and Front-Line Autologous Stem Cell Transplantation, and Allow the Definition of a Subgroup of Patients At High-Risk of Early Death From Progressive Disease
652 - Genome-Wide Aberrant Splicing in Patients with Acute Myelold Leukemia (AML) Is Associated with Altered Expression of Splicing Factors
749 - Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies
2932 - Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker
3116 - Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs
3984 - DNA Copy Number Changes Have Gene Dosage Effects with Consequent Impact On Disease Biology and Prognosis in Multiple Myeloma
4043 - Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma Cells
4044 - Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z